Declines in melanoma deaths limited to the most educated

January 16, 2012

A new study from the American Cancer Society finds recent declines in melanoma mortality rates in non-Hispanic Whites in the U.S. mainly reflect declines in those with the highest level of education, and reveals a widening disparity in melanoma mortality rates by education. The authors say the findings call for early detection strategies to effectively target high-risk, low-educated, non-Hispanic White individuals. The study is published Online First by Archives of Dermatology.

Since the early 1990s, overall melanoma mortality rates among Non-Hispanic Whites (ages 25 to 64 years) have been declining in men and women. But it has not been known whether these might differ according to socioeconomic status (SES).

To study whether melanoma death rate trends might differ according to SES, researchers led by Vilma Cokkinides, Ph. D, reviewed death certificates from 26 states, representing approximately 45 percent of the U.S. population. They found melanoma mortality declined about ten percent between over the latest ten-year span (1993-97 to 2003-07) in both men (RR= 0.916, 95% C.I.= 0.878, 0.954) and women (RR = 0.907, 95% C.I.= 0.857, 0.957).

However, declines occurred only among those with at least 13 years of education or more, irrespective of sex. In fact, there were actually non-significant increases among the least educated individuals. As a result, the educational gap in melanoma mortality rates widened by 51.7% in men and by 35.7% in women between the two time periods (1993-97 and 2003-07).

"To our knowledge, this is the first study to document this education gap in melanoma mortality trends among Non-Hispanic Whites in the U.S.," said Dr. Cokkinides. "The reasons for the widening of the educational gap in are not yet understood, but we do know the cornerstone of melanoma control is recognizing the signs of melanoma early. Lower is associated with suboptimal knowledge and awareness of melanoma, inadequate health insurance, and lower rates of skin self-examination or physician screening."

The authors conclude recent declines in melanoma mortality are largely confined to more educated groups, and that an increasingly disproportionate burden of fatal among low SES populations calls for more vigilant primary and secondary prevention education campaigns directed to high-risk, low SES individuals and the physicians that care for them.

Related Stories

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.